Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results
Date:12/10/2013

ALISO VIEJO, Calif., Dec. 10, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and twelve-months ended September 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Quarterly Financial Highlights

  • Total company net revenues of $21.7 million
  • Gross and net NUEDEXTA® sales increased to $27.7 million and $20.2 million respectively
  • Cash, cash equivalents, and restricted investments of $57.5 million as of September 30, 2013
  • "2013 has been a break-out year for Avanir," said Keith A. Katkin, president and CEO of Avanir. "We have achieved a number of important and transformational milestones. In addition to robust growth of NUEDEXTA for PBA, we formed a co-promote partnership with Merck which will leverage our commercial leadership in the institutional setting. We also in-licensed a new investigational migraine treatment, gained European approval for NUEDEXTA and initiated a new phase II study of AVP-923 exploring its potential application in levadopa-induced dyskinesias in Parkinson's disease."

    Fiscal 2013 Fourth Quarter Results

  • Total net revenues for the quarter ended September 30, 2013 were $21.7 million, compared with $13.5 million for the comparable quarter in fiscal 2012, representing approximately 61% year-over-year growth. Total net revenues consist of NUEDEXTA net revenue and royalty revenue from Abreva®.
  • Total operating expenses were $36.2 million in the fourth quarter of fiscal 2013, excluding a one-time payment of $20.0 million related to AVP-825, compared with $24.2 million in the comparable period in fiscal 2012.
  • Cash used in operations was $10.1 million, excluding a one-time payment of $20.0 million related to AVP-825.
  • Ne
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Avanir Pharmaceuticals To Present at Three Conferences In May
    2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
    3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
    4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
    5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
    6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
    7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
    8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
    9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
    10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
    11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/2/2015)... , March 2, 2015  Delcath Systems, Inc. ... medical device company focused on oncology with an emphasis ... announces that Company management will participate in the upcoming ... March 8-11, 2015 at the Ritz Carlton Laguna Niguel ... Jennifer Simpson , PhD, MSN, CRNP, Delcath,s interim President ...
    (Date:3/2/2015)... NORTH HOLLYWOOD, Calif. , March 2, 2015 ... improving the quality of life of myeloma patients ... once again declared the month of March to ... IMF first established March as Myeloma Awareness Month ... information about the disease through local community events, ...
    (Date:3/2/2015)... DUBLIN , Mar. 02, 2015 Research ... announced the addition of the "Lopinavir - ... , Imagine having your own ... of a button. Used by the ... over 10 years, these searches are the benchmark ...
    Breaking Medicine Technology:Delcath To Present At The 27th Annual Roth Conference 2Delcath To Present At The 27th Annual Roth Conference 3International Myeloma Foundation Declares March "Myeloma Awareness Month" 2International Myeloma Foundation Declares March "Myeloma Awareness Month" 3Global Comprehensive Lopinavir Patent Search Online Portal 2015 2
    ... 4, 2011 WebMD Health Corp. (Nasdaq: WBMD ... deliver a presentation at the UBS 21st Annual Global Healthcare ... ET. Investors, analysts and the general public are ... presentation over the Internet.  The broadcast can be accessed at ...
    ... K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company"), a ... informed by Hologic, Inc. that the U.S. Food and ... injection).  Makena, commonly referred to as "17P," is the ... risk of preterm birth in women with a singleton ...
    Cached Medicine Technology:FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 2FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 3FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 4FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 5FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 6FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 7FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 8FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 9FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 10FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 11FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 12
    (Date:3/2/2015)... New York (PRWEB) March 02, 2015 ... Recovery at Recovery Unplugged™—will be delivering a plenary ... Singer/Songwriter's Perspective on the Art of Healing and ... Disorders (NCAD) and Behavioral Healthcare Executive Summit (BHES).     ... name, Mr. Supa’s songs have been recorded by ...
    (Date:3/2/2015)... (PRWEB) March 02, 2015 The ... grow at a CAGR of 6.1% to reach ... 2014. , Factors such as advantages of ... healthcare costs owing to minimally invasive surgeries and ... population are driving the global minimally invasive surgical ...
    (Date:3/2/2015)... DC (PRWEB) March 02, 2015 Atlantic ... publication of AIS’s Directory of Health Plans: 2015 ... resource available on the U.S. health plan market, with ... in the United States. , Available as a ... Summary” of enrollment trends in quick-view tables and charts, ...
    (Date:3/2/2015)... (PRWEB) March 02, 2015 In light ... of anticoagulant Xarelto (rivaroxaban) tablets, Ford & ... may be helpful for future users, but may come ... injuries from taking the drug. The FDA has now ... under Adverse Reactions on Xarelto's label. The term “cytolytic ...
    (Date:3/2/2015)... ProvidaStaff has announced today that it is changing ... EDU Healthcare to reflect better on the commitment ... nationwide. , “ProvidaStaff has always been a leading healthcare ... Angela M. Lewis, President of ProvidaStaff. “We continue to ... of EDU Healthcare better aligns our services to our ...
    Breaking Medicine News(10 mins):Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3
    ... finds , WEDNESDAY, Feb. 17 (HealthDay News) -- Good ... improve their odds of staying healthy: baked rhubarb may ... garden rhubarb for 20 minutes dramatically boosted levels of ... polyphenols selectively kill or prevent the growth of cancer ...
    ... Rural areas tend to fare worse than urban locales, ... -- Want to know how healthy your county is? ... ranking of nearly every county in the nation shows ... on where they live. , Researchers from University of ...
    ... , GREENBRAE, Calif. , Feb. 17 ... of transformational media, announced today the release of Sound Sanctuaries ... Malkin . , Designed to help listeners experience deep inner peace ... moving music by Malkin that he says will "awaken the spirit ...
    ... N.C. , Feb. 17 MedCath Corporation (Nasdaq: ... they have entered into a definitive agreement to sell substantially ... David,s Healthcare Partnership, L.P. ("St. David,s"). The transaction is expected ... to customary closing conditions and regulatory requirements. , The sale ...
    ... , ... Services marked the start of 2010 with the official launch of a new state-of-the-art ... industries, this latest addition to the Almac services portfolio is set to revolutionise the ... ...
    ... MyNursingUniforms ... nursing uniform store. , ... February 17, 2010 -- MyNursingUniforms (MNU), a leader in online retail for nursing uniforms and ... , ,MNU made the expansion to their online store in both the shoe and medical ...
    Cached Medicine News:Health News:County-By-County Report Sizes Up Americans' Health 2Health News:County-By-County Report Sizes Up Americans' Health 3Health News:New CD Collections Promise to Create a Sound Sanctuary in Your Home, Office, or Car 2Health News:MedCath Enters Definitive Agreement To Sell Heart Hospital of Austin 2Health News:Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials 2Health News:Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials 3Health News:MyNursingUniforms Adds Skechers Brand Name Shoes and Scrubs to Store 2
    ... The electronic, motorized ... for all applications of ... and hard specimens in ... labs. These instruments display ...
    ... Leica RM2255 rotary microtome, designed for ... and resin-embedded specimens, offers a broad ... research histology laboratory. This microtome meets ... a compact, fully motorized/electronic microtome for ...
    State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user....
    ... system for specimen surface preparation is the ... attachment Leica SP2600. ,Ultramilling is often a ... microtomy in sample preparation. Especially with difficult ... located side by side in one specimen ...
    Medicine Products: